Proteins Are a Flu's Best Friend
Cells in the airway (indicated in red and blue) are protected by a layer of secreted mucus (in green). Credit: Michael Vahey and Daniel Fletcher.
Researchers have provided new insight on how two proteins help influenza A virus particles fight their way to human cells.
The findings, published today in the open-access journal eLife, further explain how influenza A is able to penetrate defensive mucus barriers in the airways and cause infection. This could lead to new opportunities for therapeutic interventions that disrupt this activity.
Mucosal barriers are the body’s first line of defense against influenza A infection, containing sialic acid decoys that bind the virus. To infect cells without getting stuck in the mucus, influenza A relies on a balance between two proteins on the surface of its viral particles: the receptor-binding protein hemagglutinin (HA) and the cleaving protein neuraminidase (NA). But until now, little was known about how these proteins are organised on the particles and how this may contribute to a virus’ ability to penetrate host mucus.
“We reasoned that the shape of a virus particle, together with the packaging and organisation of HA and NA, could influence the balance of attachment and detachment in ways that allow the virus to effectively penetrate mucus barriers,” says first author Michael Vahey, formerly a postdoctoral scholar at the University of California, Berkeley, US, and now Assistant Professor at Washington University in St. Louis.
To explore this, Vahey and his colleague Daniel Fletcher, also at the University of California, Berkeley, and Faculty Scientist at the Lawrence Berkeley National Laboratory, used fluorescent labelling and super-resolution microscopy to study the organisation of HA and NA on influenza A. Their work revealed that the proteins are distributed asymmetrically in such a way that the binding and cleaving leads to persistent directional motion.
“The virus appears to operate like a Brownian ratchet, with the proteins’ organisation biasing its thermally-driven motion to move through host mucus,” explains Fletcher. “This resolves the virus’s conflicting needs to both penetrate mucus and attach stably to the underlying cells.”
More work is now needed to understand if these characteristics of influenza A organisation are related to its infectivity in individuals and during host-to-host transmission. Fletcher adds that this concept may be at work in other viruses and could be a target for disruption by future treatments.
This article has been republished from materials provided by eLIFE. Note: material may have been edited for length and content. For further information, please contact the cited source.
Influenza A virus surface proteins are organized to help penetrate host mucus. Michael D Vahey, Daniel A Fletcher. eLife 2019;8:e43764 DOI: 10.7554/eLife.43764.
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.READ MORE